Current evidence on the use of the adalimumab biosimilar SB5 (ImraldiTM): a multidisciplinary perspective-Reference-Cited by-同舟云学术

Current evidence on the use of the adalimumab biosimilar SB5 (ImraldiTM): a multidisciplinary perspective

Published:2021-12-31 Issue: Volume: Page:1-13
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Gisbert Javier P.¹^ORCID,Gaffney Karl²^ORCID,Young David³^ORCID,Ebbers Hans C.⁴,Girolomoni Giampiero⁵^ORCID

Affiliation:

1. Gastroenterology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Universidad Autónoma de Madrid (UAM), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain

2. Rheumatology Department, Norfolk and Norwich Hospitals NHS Foundation Trust, Norwich, UK

3. Department of Gastroenterology, University Hospital Southampton NHS Foundation Trust, Southampton, UK

4. Biogen Intl. GmbH, Baar, Switzerland

5. Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy

Funder

Biogen International GmbH, Switzerland

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2022.2012146

Reference83 articles.

1. Biosimilar and Interchangeable Products. FDA [Internet]. 2019 [Accessed2021 May 15 2021]; https://www.fda.gov/drugs/biosimilars/biosimilar-and-interchangeable-products.

2. European Medicines Agency [Internet]. European Medicines Agency. [Accessed2019 May 15 2021]. https://www.ema.europa.eu/en

3. Biosimilar Product Information. FDA [Internet]. 2021 [Accessed2021 July 12 2021]; https://www.fda.gov/drugs/biosimilars/biosimilar-product-information

4. EMA. Humira [Internet]. European Medicines Agency. 2018 [Accessed2021 June 30 2021]; https://www.ema.europa.eu/en/medicines/human/EPAR/humira

5. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Price variability of TNF‐α inhibitor biosimilars among European countries;Journal of the European Academy of Dermatology and Venereology;2023-12-18

2. Biosimilars in Dermatology Review;Journal of Psoriasis and Psoriatic Arthritis;2023-11-03

3. The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune‐Mediated Inflammatory Disease;BioDrugs;2023-08-26

4. Healthcare Professional (HCP) and Patient Usability Evaluation and Preferences of Two Auto-injector Devices for Self-Injection of Biosimilars, SB4 and SB5: A Literature Review;Clinical Drug Investigation;2023-08

5. Real‐world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA‐SWITCH study;Alimentary Pharmacology & Therapeutics;2023-04-23